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Abstract
Background: Tuberculosis (TB) surveillance programs in Canada have established that TB in
Canada is becoming a disease of geographically and demographically distinct groups. In 1995, treaty
status aboriginals from the province of Manitoba accounted for 46% of the disease burden of this
sub-group in Canada. The TB incidence rates are dramatically high in certain reserves of Manitoba
and are equivalent to rates in African countries. The objective of our study was to identify prevalent
isolates of Mycobacterium tuberculosis in the patient population of Manitoba using molecular
epidemiology tools, studying the patient demographics associated with the prevalent strain and
studying the in vitro cytokine profiles post-infection with the predominant strain.
Methods: Molecular typing was performed on all isolates available between 1992 to1997. A clinical
database was generated using patient information from Manitoba. THP-1 cells were infected using
strains of M. tuberculosis and cytokine profiles were determined using immunoassays for cytokines
IL-1β, IL-10, IL-12, IFN-γ and TNF-α.
Results: In Manitoba, 24% of the disease burden is due to a particular M. tuberculosis strain (Type1).
The strain is common in patients of aboriginal decent and is responsible for at least 87% of these
cases. Cytokine assays indicate that the Type1 strain induces comparatively lower titers of IL-1β,
IFN-γ and TNF-α in infected THP-1 cells as compared to H37Ra and H37Rv strains.
Conclusion: In Manitoba, Type1 strain is predominant in TB patients. The majority of the cases
infected with this particular strain are newly active with a high incidence of respiratory disease,
positive chest radiographs and pulmonary cavities. In vitro secretion of IL-1β, IFN-γ and TNF-α is
suppressed in Type1 infected culture samples when compared to H37Ra and H37Rv infected cells.
Background
Epidemiology of tuberculosis
Tuberculosis (TB) infects one-third of the world popula-
tion and causes approximately 3 million deaths annually
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[1–4]. The average incidence rate for tuberculosis is 5.9
per 100,000 population in Canada and 9.2 per 100,000
population in the Canadian province of Manitoba [3,5].
In Canada, the majority of TB cases in most provinces are
attributed to immigration. Of all the TB cases in each of
the provinces of Ontario, British Columbia and Quebec,
foreign born cases represent majority of the cases (81%,
60% and 48% of the cases, respectively) while foreign
born cases represent only 29% of the total TB cases in
Manitoba [3]. In Manitoba, the composition of TB pa-
tients is distinctly different from that of other Canadian
provinces as the majority of TB cases are among Canadi-
an-born individuals, with the highest incidence among
treaty (registered) aboriginals (48.4 per 100,000 overall,
with rates as high as 496.3 per 100,000 in select commu-
nities) [3]. 'Aboriginals' or 'first nations' describe the in-
digenous Canadians and their descendants,
encompassing those registered as status aboriginals,
Métis, Innu and Intuit individuals that may live on or off
reserves. In the past few decades, incidence rates of TB
have declined in every sub-population, however rates
among Canadian-born treaty individuals in Manitoba
(48.4 per 100,000) are still more than ten times higher
than for non-treaty subgroup (3.3 per 100,000) and more
than two times higher than for the foreign-born subgroup
(22.0 per 100,000) [3–6]. Canadian surveillance studies
have shown that TB is prevalent in geographically and de-
mographically distinct groups, such as, foreign-born and
aboriginal individuals [5]. These groups have sustained a
steady level of incidence and are in need of targeted TB
control measures, with treaty status sub-population con-
tributing to the majority of the current burden of incident
cases [5]. The incidence rate of TB among treaty status ab-
originals (48.4 per 100,000) was five times higher than
the overall provincial rate (9.2 per 100,000) and eight
times higher than the national rate of TB (5.9 per
100,000). The incidence rate of TB in treaty status aborig-
inals is probably an underestimate as the number of abo-
riginal individuals that have not claimed treaty status is
unknown.
Manitoba has a population of 1.15 million of which
78.1% are Canadian-born (CB) non-treaty, 8.9% are trea-
ty aboriginals, and the remainder (13%) are foreign-born
(Statistics Canada census, 2002). The majority of Manito-
ba residents live in the capital city of Winnipeg (685,500).
There are 139 reserves in Manitoba; reserves are tracts of
land whose legal title is held by the Federal Crown and
which has been set apart for use and benefit of a particular
First Nation community (Statistics Canada census, 2002,
Province of Manitoba, 2000). All of the TB cases in the
province are reported to TB control program that moni-
tors provincial TB patient registry, hospitals, clinics and
diagnostic TB laboratories in Manitoba [5].
Currently available molecular diagnostic techniques such
as Restriction Fragment Length Polymorphism (RFLP) us-
ing the insertion sequence IS6110, secondary probes
(pTBN12), and spoligotyping, permit strain identification
within species with a higher degree of specificity com-
pared to traditional methods [7–11]. These techniques
help to confirm or identify the chain of transmission and
the distribution of strain clusters, allowing insight into the
molecular evolution of the species [7,12–14]. The most
widely used method is IS6110-RFLP typing of Mycobacteri-
um tuberculosis (M. tuberculosis) which relies on repetitive
DNA insertion sequence with a length of 1361 bp and is
specific to the M. tuberculosis complex [7,10]. In our labo-
ratory, IS6110-RFLPtyping was performed on 479 patient
isolates and we analyzed the predominant RFLP patterns
among these isolates.
Host responses to tuberculosis
TB infection is a competitive balance between the bacteri-
um, M. tuberculosis trying to establish itself within the host
tissues and host cellular defense mechanisms striving to
overcome the infection. The progression of the disease is
governed by both host genetic factors and interactions be-
tween the host and parasite [15–18]. Host defenses de-
pend mostly on cell mediated immunity, primarily T
lymphocytes and macrophages [16]. Macrophages are the
first cells to encounter M. tuberculosis in lungs of the host
and they react to the parasite by producing a distinct pat-
tern of cytokines including; Interleukin-1 (IL-1), IL-2, IL-
10, IL-12, tumor necrosis factor-alpha (TNF-α) and inter-
feron-gamma (IFN-γ) [16,19]. The pro-inflammatory cy-
tokines, such as IL-1, IL-12, TNF-α and IFN-γ as well as
anti-inflammatory cytokine IL-10 were analyzed in this
study [19–21]. In this study, the patient demographic and
geographic factors associated with the prevalent clinical
isolates were studied. To investigate whether this preva-
lent M. tuberculosis strain was virulent, we examined the in
vitro growth rate of these bacilli and the cytokine respons-
es in THP-1 cells following infection with M. tuberculosis
strains.
Methods
DNA Fingerprinting
479 isolates were available from 610 TB patients (1992–
1997) at The Mycobacteriology Laboratory, Health Sci-
ences Centre, Winnipeg. The mycobacterial genomic DNA
was extracted and purified using conventional methods
[11,22]. The digestion of genomic mycobacterial DNA us-
ing PvuII was carried out as described by Van Embden et al
[22] with a few modifications [10,12]. The digested DNA
was transferred onto the nylon membrane, probed over-
night with DIG-labeled IS6110  probe at 65°C and ex-
posed to X-ray film for 15–20 minutes. Fingerprint
pattern images were captured using GelDoc (Bio-Rad,
Hercules, CA) and analyzed using Molecular AnalystBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/3
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Software-fingerprinting version 1.1 (Bio-Rad). Computer
assisted phylogenetic analysis was employed to character-
ize strains and assess banding pattern similarities. Numer-
ical designations were arbitrarily assigned to strains
according to their prevalence in the population under
study.
Data collection
A total of 115 TB patient records were screened for this
study between 1992–1997 and were obtained from the
Provincial TB Registry, Manitoba. The data fields such as
age, sex, race, origin, disease diagnosis, chest X-ray, the
presence of cavitary disease and residential location were
extracted from the patient records and the information
was entered into a database. This data was blinded, allow-
ing data analysis while maintaining the patient
confidentiality.
Immunology
Bacterial strains
M. tuberculosis strain H37Ra (ATCC 25177), H37Rv
(ATCC 25618) and Type1 were cultured for 6 weeks on
Middlebrook 7H10 agar media [23]. Bacilli were harvest-
ed at mid-log phase and adjusted to 1 × 107 cells per ml in
phosphate buffered saline (PBS). Colony counts and pu-
rity checks were performed on these cultures [24].
Culture of macrophages
Human mononuclear cell line, THP-1 (ATCC TIB-202),
was used in our experiments. THP-1 cells are phagocytic in
nature and can be induced to differentiate into macro-
phage-like cells [25]. The cells were cultured in RPMI-
1640 media (Sigma, ON, Canada) supplemented with
10% fetal bovine serum (FBS, Sigma) and 1% streptomy-
cin-penicillin antibiotic (Sigma). Cells were stained with
trypan blue (Sigma) and the number of viable cells were
determined using a hemacytometer [23,25].
Monocyte stimulation
THP-1 cells (2 × 106 cells) grown in RPMI media supple-
mented with 5% FBS and without antibiotic, were infect-
ed with 2 × 107 colony forming units of either of H37Ra,
H37Rv and Type1 M. tuberculosis strains. Uninfected PBS
was used as a negative control. Colony counts of myco-
bacteria were determined at each time point post-infec-
tion by subculturing serial dilutions of the cultures onto
Middlebrook 7H10 plates. Supernatants were collected at
different time intervals i.e., 0.25, 2, 4, 6, 8, 24, 48, 72
hours post-infection by centrifugation at 3000 × g for 20
minutes at 15°C and were then aliquoted and stored at -
20°C until used [20,24].
Enzyme Linked Immunosorbent Assay
Enzyme Linked Immunosorbent Assay (ELISA) was car-
ried out in triplicate for each infection using commercially
available antibody pairs for cytokines IL-12, IL-1β, IFN-γ,
TNF-α and IL-10 in accordance to manufacturer's instruc-
tions® & D Systems, Minneapolis). Each assay was run
with a negative control (PBS) and blank samples (accord-
ing to manufacturer's instructions). The average zero
standard optical density was subtracted from different
standard and sample optical densities. Sample concentra-
tions were calculated using a standard curve. The results
were expressed as amounts of cytokine in picograms per
milliliter (pg/ml). The average values were calculated
from six independent trials which were each analyzed in
triplicate.
Statistical analysis
Data was statistically analyzed using SAS software (ver-
sion 7.0, Cary, North Carolina). Results were derived from
six independent experiments, each carried out in tripli-
cate. Cytokine results were correlated at each time point
using a non-parametric correlation coefficient. Each im-
munological (cytokine) variable was analyzed using a
two-way ANOVA correlating group and time interaction,
followed by least square means multiple comparisons
with bonferroni corrections.
Results
Type1 Epidemiology
Between 1992 and 1997, there were 610 TB positive pa-
tients in Manitoba. There are 194 M. tuberculosis strains
isolated from 479 patients from Manitoba and the top 5
strains are Type1, Type5, Type2, Type72, Type71 that are
responsible for 24%, 5%, 4.6%, 4.2% and 2% of the total
TB cases, respectively. The predominant group of isolates
(115/479 cases; 24%) showed a similar banding pattern,
which we referred to as fingerprint 'Type1'. As 1 in 4 pa-
tients were infected with Type1, we screened patient
records for cases which depicted this fingerprint pattern.
Of all Type1 cases reported in the province of Manitoba,
Winnipeg, the capital city of Manitoba alone accounted
for 70/115 cases (60.8%) of the cases. Among Type1 pa-
tients residing in cities, 98.5% of the individuals lived in
the city of Winnipeg. In areas other than cities, 93% of the
Type1 patients lived on aboriginal reserves. Winnipeg and
aboriginal reserves appear to be reservoirs of Type1 strain.
The majority of the Type1 cases were newly active (91/115
cases; 79%). This strain causes disease in the younger
groups with an age range of 21–50 years (84/115 cases;
73%). Within this group, patients with an age range of
31–40 yrs (31/115 cases; 26.9%) are at the most risk of
developing disease due to this strain. Infection from this
strain appears to be more prevalent among males (73/115
cases; 63%). The majority of treaty and non-treaty status
aboriginal people (100/115 cases; 87%) had this Type1
strain isolated from their cultures. Of a total of 100 abo-
riginal cases, 85 (85%) had treaty status and 15 (15%)
were non-treaty status aboriginals. Radiograms of theBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/3
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patients show that many of Type1 cases exhibited respira-
tory disease (104/115 cases; 90%) and some (22/115 cas-
es; 19%) had developed pulmonary cavities.
In vitro cytokine production post-infection
We examined the in vitro response of human THP-1
monocytes to infection with M. tuberculosis H37Rv,
H37Ra and the Type1 strain (See methods). Colony
counts (measured in cfu) were obtained post-infection at
0.25, 2, 4, 6, 8, 24, 48 and 72 hrs to determine the log dif-
ference in colony forming units over time. Differences in
the cfu log10 values [log10(max)-log10(min)] of M. tuber-
culosis strains at 0.25, 2, 4, 6, 8, 24, 48 and 72 hrs post-
infection were 0.2 for H37Ra, 0.15 for H37Rv and 0.16 for
Type1 strain. At any time point, differences in the cfu
log10 values between H37Ra, H37Rv and Type1 were also
insignificant (Difference in log10 values ≤ 0.15).
Levels of IL-12, IL-1β, IFN-γ, TNF-α and IL-10 were meas-
ured in M. tuberculosis infected cell cultures. The levels of
the forementioned cytokines were determined at 0.25, 2,
4, 6, 8, 24, 48 and 72 hrs post-infection in order to ob-
serve any change of profile during this time period.
IFN-γ
Secretion of IFN-γ was highest in supernatants of H37Rv
infected cells (p < 0.05) in comparison to cells infected
with H37Ra or Type1 strains (Fig. 1). IFN-γ secretion was
consistently low in Type1 infected cultures, compared to
the control (6–72 hrs post-infection; p < 0.033), H37Ra
infected cells (0.25–72 hrs post infection; p < 0.02) and
Figure 1
IFN-γ secretion in THP-1 cells infected with H37Ra, H37Rv and the Type1 strains of M. tuberculosis.
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H37Rv infected cells (0.25–48 hrs post infection; p <
0.02). These results show that the expression of IFN-γ was
suppressed in cells infected with the Type1 strain (Fig. 1).
IL-1β
IL-1β levels were significantly lower in supernatants in-
fected with the Type1 compared to those from superna-
tants infected with the H37Rv strain (2–72 hrs post
infection; p < 0.0001). In comparison to the Type1,
H37Ra infected cultures showed a sustained increase in
IL-1β secretion at 24 hours post-infection (p < 0.01) (Fig.
2).
TNF-α
TNF-α secretion was higher in supernatants of H37Rv in-
fected cells (8–72 hrs post-infection, p < 0.005) than in
supernatants of cultures infected with other strain types
and controls (Fig. 3). Secretion of TNF-α in Type1 infected
cells was higher than for H37Ra infected cells. TNF-α se-
creted was stable from 8–72 hours inType1 infected cells
(Fig. 3).
IL-10
IL-10 secretion in Type1 infected cells was elevated (p <
0.05) at 0.25–4 hrs post-infection as compared to secre-
tion in H37Ra and H37Rv infected cells and controls (Fig.
4). The level of IL-10 in the Type1 infected cells were sta-
tistically insignificant at other time points as compared to
cells infected with H37Ra and H37Rv.
Figure 2
IL-1β secretion in THP-1 cells infected with H37Ra, H37Rv and the Type1 strains of M. tuberculosis.
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IL-12
Levels of IL-12 were undetectable in all infected cells at all
given time points.
Discussion
Epidemiology
Different  M. tuberculosis strains have different rates of
transmission in a population. IS6110-RFLP analysis has
shown that some strains of M. tuberculosis are more capa-
ble of causing disease outbreaks than other strains
[11,26]. Our epidemiological investigations have shown
that the Type1 strain causes cluster outbreaks with a high
rate of active infection and accounts for 24% of all TB cas-
es in Manitoba. This strain is prevalent among infected in-
dividuals of aboriginal decent (87%) [3]. Until recently, it
was believed that the high prevalence of this strain was
secondary to socioeconomic factors. However, these fac-
tors alone do not account for the high prevalence of Type1
strain and the high incidence of patients displaying newly
active disease, respiratory disease, positive radiograms
and pulmonary cavities. A study by our collaborators has
also demonstrated the occurrence of central nervous sys-
tem (CNS) TB may be strain dependent and that Type1
strain was significantly associated with the number of
CNS TB positive cases [27]. A recent study conducted by
Manca et al has shown that different clinical isolates may
elicit different responses in vivo and may be designated as
virulent or hypervirulent [28,29]. We were interested in
studying Type1 strain as it is responsible for approximate-
ly one in four cases of TB in Manitoba and 9 of 10 TB cases
in the aboriginals of Manitoba. The probability that this
strain has a higher potential to cause disease in infected
subjects must be explored further using different methods
such as in vitro and in vivo host responses and in vivo sur-
Figure 3
TNF-α secretion in THP-1 cells infected with H37Ra, H37Rv and the Type1 strains of M. tuberculosis.
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vival studies. In this study, we studied in vitro host re-
sponse in cells infected with Type1 by estimating the
secretion levels of four pro-inflammatory and an anti-in-
flammatory cytokines over a period of time (0.25–72 hrs).
Mycobacterial Growth
The colony count data shows that the growth of all M. tu-
berculosis strains was similar throughout the experiment.
The doubling time for M. tuberculosis varies from 20–30
hrs, and since our THP1 infection experiments were car-
ried out over a total of 72 hrs, the bacilli could only have
gone through 2–3 cycles of replication. In addition, M. tu-
berculosis requires specialized growth media (Lowenstein
Jensen, Middlebrook 7H10, 7H9, BACTEC 12B etc.) and
since our infection experiments were carried out using a
non-specific M. tuberculosis growth media (RPMI), it may
explain the insignificant difference in the growth (log10
values) of M. tuberculosis strains.
Cytokine responses
Cytokines play a key role in the success of the host im-
mune response against mycobacterial infection and in the
pathogenesis of TB. In TB, the host responses are provided
by T cells and macrophages [16,19,20]. Indeed, macro-
phages are the first cells of the immune system that are ex-
posed to M. tuberculosis. They act by engulfing the bacilli,
producing proteolytic enzymes, presenting mycobacterial
antigens to T cells and producing a characteristic pattern
of cytokines that regulate the immune system and medi-
ate many of clinical manifestations of TB [16]. We used a
human THP-1 monocytic cell line in vitro and carried out
mycobacterial infections with H37Ra, H37Rv, Type1
strains and PBS control. THP-1 cells are phagocytic in na-
Figure 4
IL-10 secretion in THP-1 cells infected with H37Ra, H37Rv and the Type1 strains of M. tuberculosis.
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ture and can differentiate into mature cells that function
as macrophages that are capable of producing cytokines
such as IL-1, IL-8, IL-6, IL-10, IL-12p40 and TNF-α [25].
Our results demonstrate that there is a specific pattern of
cytokines secreted by infected THP-1cells. Titers for most
of the pro-inflammatory cytokines as IFN-γ, IL-1β and
TNF-α were highest in cells infected with H37Rv strain.
Type1 infected cells expressed lower amounts of these cy-
tokines as compared to H37Ra and H37Rv infected cells.
Although IL-12 is an important pro-inflammatory cy-
tokine that favors Th1 host immune responses and is di-
rectly responsible for the outcome of the TB infection, it
was not detected in sufficient amounts in our system
[30,31]. There are several possible explanations for this
observation. Firstly, perhaps M. tuberculosis organism itself
is unable to induce sufficient amounts of IL-12 in THP-1
cells [30,31]. Secondly, negative stimulators of IL-12 pro-
duction such as IL-10 and IL-4 may counteract pro-in-
flammatory effects of IL-12 [31]. Finally, we cannot
exclude the possibility that IL-12 secretion may be myco-
bacterial dose dependent. Other methods such as RT-PCR
may be used to detect IL-12 levels more effectively than
the method used in this study.
It is known that IFN-γ enhances the antimicrobial activity
of macrophages through increased production of hydro-
gen peroxide and nitric oxide metabolites, while inhibit-
ing the proliferation of Th2 cells and the secretion of Type
2 cytokines [32–34]. IFN-γ secretion was depressed in cells
infected with the Type1 and hence these low levels were
insufficient to induce the macrophages to secrete IL-12
(Fig. 1). Both IFN-γ and TNF-α are required for protective
host immunity to TB infection [34–38] and the produc-
tion of [30,31] low expression levels of IFN-γ are likely re-
sponsible for the impaired protective immune cascade to
a greater extent in Type1 infected cells than H37Rv infect-
ed cells. Furthermore, mixed cell culture experiments con-
taining T-lymphocytes may be a more favourable model
to study IFN-γ production as T-lymphocytes are a more
important cellular source of IFN-γ than monocytes. Stud-
ies using animal models may provide a better experimen-
tal model to study this cytokine.
IL-1 is produced upon stimulation by M. tuberculosis cell
wall components and mycobacterial proteins [16]. IL-1
secretion upregulates T-cell expression of IL-2 and IL-2 re-
ceptors, induces macrophages to produce other pro-in-
flammatory cytokines such as IL-6 and TNF-α and may
contribute to development of fever [16,36]. The compara-
tively lower concentrations of IL-1β in Type1 infected cells
may have resulted in lesser TNF-α secretion (Fig. 2), thus
providing a more stable environment for the strain to
propagate or reside within the host cell.
TNF-α secretion was detected for all the strains from 0.25–
8 hrs but thereafter was higher in H37Rv and Type1 infect-
ed cells (Fig. 3). Similar titers of TNF-α at 0.25–8 hrs. post-
infection with all M. tuberculosis strain can be attributed to
M. tuberculosis as well as its cell wall components and pro-
teins. In vitro and in vivo studies from other laboratories
have shown that mycobacterial components induce high-
er amounts of TNF-α in virulent M. tuberculosis strains as
compared to avirulent strains [16,26]. This phenomenon
was evident in our experiments from cells infected with
virulent strains (24–72 hrs of post infection). However,
TNF-α secretion does not complement secretion pattern
of other pro-inflammatory cytokines under investigation
in Type1 infected cultures. As TNF-α exhibits both protec-
tive immunity, in terms of anti-mycobacterial activity and
development of granulomas and pathological effects, in-
cluding symptoms such as fever and wasting. It is perhaps
best to study this cytokine in vivo using animal models
whereby a distinction could be made as to which effect is
predominant [16,21].
Anti-inflammatory cytokines, such as IL-10, suppress pro-
duction of the pro-inflammatory cytokines such as IL-12.
This process of downregulation of pro-inflammatory cy-
tokines could prove to be deleterious to the host [19]. IL-
10, an anti-inflammatory cytokine, inhibits pro-inflam-
matory cytokine synthesis by monocytes and macrophag-
es [20,39]. Following infection, IL-10 levels in Type1
infected cells were high and subsequently were the similar
for H37Ra and H37Rv infected cells (Fig. 4). Similar find-
ings have been demonstrated with other M. tuberculosis
strains in both in vitro and in vivo studies using animal
models as well as in clinical studies [20,35,40].
Upon infection, host cells come into contact with myco-
bacterial components such as LAM and mycobacterial
proteins of molecular weight 20 and 46 kDa and secrete
IL-1 and TNF-α. TNF-α is also produced by other myco-
bacterial proteins of molecular weight 44, 58, 65 kDa
[15,21,30,37]. Compared to other strains under investiga-
tion, Type1 infected cells produced lower levels of IL-1
which may have lead to the ineffective host immune re-
sponse, also resulting in lesser bacillary elimination in
these cells. On the other hand, high levels of TNF-α are se-
creted in host cells infected with virulent strains of M. tu-
berculosis and this data is consistent with TNF-α secretion
in Type1 infected cells [15,26]. TNF-α along with other
pro-inflammatory cytokines, such as IFN-γ, activates the
macrophages to produce inducible nitric oxide synthase
and reactive nitrogen intermediates, which cause reduc-
tion of mycobacterial growth but fails to eliminate the
pathogen [21,30,33,37]. Contrary to pro-inflammatory
cytokines, anti-inflammatory cytokines act by downregu-
lating host immune response and limiting host tissue in-
jury and are primarily produced upon infection by M.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/3
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tuberculosis  [16,20,41]. Excessive IL-10 production at
0.25–4 hrs post-infection may have contributed towards
loss of control of infection [20,35,40]. Supportive evi-
dence has shown that elevated levels of TNF-α and IL-10
have been detected in patients with lung TB
[20,35,39,40]. TB disease is better controlled when the
host rapidly develops pro-inflammatory cytokine re-
sponse in infected cells. On the other hand, disruption of
the balance between pro- and anti-inflammatory cy-
tokines by absence or suppression of pro-inflammatory
cytokine response and predominance of immuno-sup-
pressive cytokines, as depicted by Type1 infected cells,
may be associated with early development of disease. If
these results are replicated in vivo and are correlated with
disease progression, they may better explain the predom-
inance and virulence of Type1 strain in the Manitoba.
Conclusion
The pathogenesis of TB depends on a combination of M.
tuberculosis virulence factors and host factors. Results from
this study indicate that Type1 strain has a unique epidemi-
ology as well as a specific cytokine profile, which confers
it the ability to modulate host immune response in its fa-
vour. These factors may explain the propensity of the
Type1 strain in Manitoba, especially among its aborigi-
nals. These findings must be confirmed in vivo using
mouse models which will help us to better understand the
pathogenesis of the M. tuberculosis Type1 strain. We are
currently studying the in vivo survival rate, clearance or
non clearance of infection and immunological responses
of mice infected with Type1 and other clinical strains. This
would not only provide evidence of strain related viru-
lence but the immunological profiles could also be used
to modulate host immune response to enhance therapy of
TB.
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